Sign in
4

Changes in Ownership

Nurix Therapeutics, Inc. Filed Acc 0001209191-22-043961

Chief Scientific Officer sold 1,186 shares at $15.67 ($18,585)

  • Chief Scientific Officer acquired 3,207 shares (option exercise)

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Hansen Gwenn Chief Scientific Officer 2022-07-30 Option exercise +3,207 20,358 D: show line 1 in the form
Hansen Gwenn Chief Scientific Officer 2022-08-01 Sale −1,186 $15.67 $18,585 19,172 D: show line 2 in the form
Open-market sales · 1,186 sh · avg $15.67 · $18,585

Table II: Derivative

Insider Date Transaction Shares Price Value Exercise Expires Underlying Owned after D/I
Hansen Gwenn Chief Scientific Officer 2022-07-30 Option exercise · Restricted Stock Units −3,207 44,895 D: show line 3 in the form
Loading xslF345X03/doc4.xml…